NCT02433626View on ClinicalTrials.gov

Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies

PHASE1UnknownINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

December 31, 2019

Study Completion Date

June 30, 2020

Conditions
Ovarian CancerFallopian Tube CancerEndometrial CancerCervical CancerPeritoneal CancerHead and Neck CancerHNSCCColorectal CancerLung CancerPancreatic Cancer
Interventions
DRUG

COTI2

COTI-2 is a third generation thiosemicarbazone.

DRUG

Cisplatin

Cisplatin is approved to treat a range of solid tumors and lymphomas.

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

M.D. Anderson Cancer Center

OTHER

collaborator

Northwestern Memorial Hospital

OTHER

lead

Critical Outcome Technologies Inc.

INDUSTRY